In this issue:
Tolerance and efficacy of BRAF-MEK inhibition after prior PD-1 therapy for melanoma
Role of elevated LDH in patients with melanoma treated with immunotherapy and BRAF inhibitors
Population-based validation of US NCC guidelines for baseline imaging workup of cutaneous melanoma
Clinical experience with BRAF/MEK inhibitors for melanoma with brain metastases
Clinicopathologic features and outcomes in stage IIC vs IIIA melanoma
Economics of T-VEC + ipilimumab vs ipilimumab monotherapy in advanced unresectable melanoma
Outcomes and risk factors in patients with multiple primary melanomas
Predictors of sentinel lymph node positivity in thin melanoma
Sun protection behaviour after diagnosis of high-risk primary melanoma
31-gene expression profile to identify risk of metastasis in melanoma
Please login below to download this issue (PDF)